Doctors suggested that a drug Sitagliptin Hepatitis C, a drug to lower blood sugar in type 2 diabetes, also enhances hospitalization for people with diabetes with a virus COVID-19 , According to a multicenter study in Italy.
According to the study, which included 7 Italian hospitals during the first wave of cases COVID Last spring, the patients were treated with a drug sitagliptin In addition to insulin, they had a mortality rate of 18% compared to 37% in matched patients receiving insulin only.
Although the study was retrospective and observational, the results – published in the Journal of Diabetes Care – launched a new randomized placebo-controlled trial of the drug. sitagliptin . This study is now preparing to enroll patients in Europe.
“We think it would be reasonable to try sitagliptin if a patient is hospitalized with type 2 diabetes and COVID”
Based on how it works sitagliptin , The medical team believes, it can also work with patients without disease Diabetics have COVID
Sitagliptin An oral medication is a class of drugs known as inhibitors DPP-4 It is prescribed to about 15 to 20% of people with type 2 diabetes, was approved by the Food and Drug Administration in 2006, and lowers blood sugar by blocking the enzyme receptor. DPP-4 (Also known as CD26), Causing insulin production to increase.
But recent studies indicate that DPP-4 It might also help SARS-CoV-2 Coronavirus that causes COVID-19 – into the cells of the respiratory system. In addition to preventing DPP-4 , Then sitagliptin It has anti-inflammatory effects, which reduces cytokine production IL-6 , Which is known to contribute to a “cytokine storm” that can cause complications in the organs COVID-19.
It may be for Sitagliptin Also, a third benefit: keeping blood sugar levels low, previous studies have shown that diabetics with poor blood sugar control have worse outcomes than COVID-19.
Study design and results
The study included 338 consecutive patients with type 2 diabetes and pneumonia COVID-19 Who were admitted to 7 academic hospitals in Northern Italy from 1 March until 30 April 2020. Of these, only 169 patients were given intravenous insulin for type 2 diabetes (standard of care) and acted as controls; The other 169 received sitagliptin In addition to intravenous insulin. The two groups were matched for age and gender, and their results were analyzed retrospectively.
Disease severity, other clinical characteristics, and use of other treatments for COVID-19 The two groups are similar. Compared to controls, patients receiving sitagliptin They reduced the mortality rate (18% versus 37%) and were more likely to improve clinically.
Specifically, the researchers concluded that the patients treated with B. sitagliptin:
- Less likely to need mechanical ventilation (hazard ratio, 0.27, or 27% probability compared to controls)
- Less likely to need intensive care (risk ratio 0.51)
- You are likely to have a reduction of at least 2 points on a 7-point scale of disease severity (52%, versus 34% of the control group).
- Less likely to worsen clinical outcomes, as defined by any increase in clinical severity (26 percent versus 46 percent).